Newsletter | April 29, 2025

04.29.25 -- Trends In U.S. Biomanufacturing: From Cell Line Development To Commercial Scale

Prioritizing R&D Initiatives To Support Cell Line Development

As drug discovery accelerates, the demand for advanced cell line development grows. See how a CDMO with a strong R&D focus can drive faster timelines, improved efficiency, and better outcomes for your biologic pipeline.

 

Diversifying Single-Use Technology With Cytiva XDR Bioreactors

Need to scale up without losing control? Explore how access to flexible single-use bioreactor systems, including the Cytiva Xcellerex Disposable Reactors, can efficiently scale your production while maintaining process consistency and product quality.

 

From Bench To 20k L Bioreactor: Optimizing Cell Culture Scale-Up

Master scale-up strategies, optimize key parameters, and ensure a seamless transition from bench to large-scale bioreactors for a thriving biopharmaceutical process.

 

10 Minutes On Optimizing Upstream Process Development

Gain insight into how UPD ensures scalable and compliant processes, facilitates the efficient development of innovative therapeutics, and contributes to molecule development and production.

 

IN THE NEWS

 

AGC Biologics' Seattle Site Achieves Successful Multi-Product Inspection By U.S. Food And Drug Administration For Biologics License Applications

AGC Biologics’ Seattle Campus completed a new commercial milestone for regulatory compliance, completing a multi-product inspection with the FDA to support Biologics License Applications (BLA) for three new products seeking commercial approval in the U.S., all of which are now approved.

SOLUTIONS

Seattle CDMO Site Takes On The Complex Molecules

Discover how our Seattle campus can support your pharmaceutical development needs with cutting-edge capabilities, expert team, and seamless global project transfer.

• Request Information